Sapey, E. http://orcid.org/0000-0003-3454-5482
Crowley, L. E. http://orcid.org/0000-0001-6261-5041
Edgar, R. G. http://orcid.org/0000-0002-5971-3035
Griffiths, D.
Samanta, S.
Crisford, H.
Bolton, C. E. http://orcid.org/0000-0002-9578-2249
Hurst, J. R. http://orcid.org/0000-0002-7246-6040
Stockley, R. A. http://orcid.org/0000-0003-3726-1207
Funding for this research was provided by:
Alpha-1 Foundation
Article History
Received: 26 April 2023
Accepted: 3 March 2024
First Online: 21 March 2024
Declarations
:
: This project was approved by the Health Research Authority and National Research Ethics Committees (REC). Three cohorts of participants were recruited in Birmingham; the AATD registry (REC:3359a), the West Midlands COPD database (REC:12/EM/0090) and a cohort without COPD or AATD (termed healthy controls (HC)) (REC:15/WM/0002). Some AATD patients were recruited from the Royal Free London NHS Foundation Trust (RFH) AATD clinic (REC:13/LO/1085).
: Not applicable. All research procedures took place after gaining informed written consent.
: E. Sapey reports grant funding from NIHR, MRC, HDR-UK, Innovate UK, British Lung Foundation and Alpha 1 Foundation; L.E. Crowley, R.G. Edgar, D Griffiths, S. Samanta and H Crisford have no relevant conflicts of interest, C.E. Bolton reports grants from Glaxo Smith Kline and British Lung Foundation and consultancy fees from AstraZeneca, J.R. Hurst reports consultancy fees and honoraria from AstraZeneca, Boehringer Ingelheim, Takeda, Nonin, and the British Thoracic Society. R.A. Stockley reports investigator led grant funding from the Alpha 1 Foundation, CSL Behring, Mereobiopharma and Data Safety Monitoring Board and Advisory Board participation for DSMB Kamada, Vertex, CSL, Z Factor and Inhibrx.